Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
Ramón Teira(Hospital Sierrallana), Adrián Curran(Lexington City Schools), María Dolores Merino(Hospital Universitario Infanta Leonor), Juan Berenguer(Instituto de Salud Carlos III), Helena Díaz-Cuervo(Gilead Sciences (Spain)), Maria Jose Muñoz-Sánchez(Hospital de Basurto), Marta Montero, Alberto Romero-Palacios(Hospital Universitario Puerto Real), Peré Domingo(Hospital de Sant Pau), Elisa Martínez(University Hospital and Clinics), Elisabeth Deig(Hospital General de Granollers), Manuel Castaño, Paloma Geijo(Hospital Virgen de la Luz), Filipa Aragão(Universidade Nova de Lisboa), María Antonia Sepúlveda(Hospital Virgen de la Salud), Belén de la Fuente(Hospital Universitario De Cabueñes), Bernardino Roca(Hospital General Universitari de Castelló), Joaquim Peraire(Instituto de Salud Carlos III), Marı́a José Galindo(Hospital Clínico Universitario de Valencia), Núria Espinosa, Josefina García(Santa Lucía University General Hospital), Vicente Estrada(Instituto de Salud Carlos III)
Cited by 6
Related Papers
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
|Clinical Microbiology and Infection|2020|423